Revvity cut its 2024 revenue forecast as reduced biotech spending and a strong dollar weigh on demand for its tools and services used in drug development. The diagnostic products and scientific tools ...

is pleased to introduce the world's first SPR instrument subscription plan, exclusively designed for early-stage biotech startups. This new offering is part of the Alto Lab Catalyst Program ...